4,4-Dimethyl-3-[[3-(1,3-thiazol-2-yl)phenyl]methyl]-1-[4-(trifluoromethylsulfanyl)phenyl]-1,3-diazinan-2-one

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4,4-Dimethyl-3-[[3-(1,3-thiazol-2-yl)phenyl]methyl]-1-[4-(trifluoromethylsulfanyl)phenyl]-1,3-diazinan-2-one
• 英文别名: 4,4-dimethyl-3-[[3-(1,3-thiazol-2-yl)phenyl]methyl]-1-[4-(trifluoromethylsulfanyl)phenyl]-1,3-diazinan-2-one
• 化学式: C₂₃H₂₂F₃N₃OS₂
• 分子量: 477.6
• InChiKey: BCGNBIJXSAJKCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  90
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• [EN] TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF<br/>[FR] INHIBITEURS DE KINASE TRK-A, COMPOSITIONS ET MÉTHODES CORRESPONDANTES
  申请人：MERCK SHARP & DOHME

  公开号：WO2013176970A1

  公开（公告）日：2013-11-28

  The present invention is directed to benzyl urea compounds, which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.

  本发明涉及苄基脲化合物，它们是肌动蛋白相关激酶（Trk）家族蛋白激酶抑制剂，因此可能在治疗疼痛、炎症、癌症、再狭窄、动脉粥样硬化、银屑病、血栓形成、与失髓鞘化或脱髓鞘化有关的疾病、紊乱、损伤或功能障碍，或与神经生长因子（NGF）受体Trk-A、Trk-B和/或Trk-C异常活动相关的疾病或紊乱方面有用。
• TrkA Kinase Inhibitors, Compositions and Methods Thereof
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150141428A1

  公开（公告）日：2015-05-21

  The present invention is directed to benzyl urea compounds, which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.

  本发明涉及苯甲基脲化合物，它们是肌动蛋白相关激酶（Trk）家族蛋白激酶抑制剂，因此可能有用于治疗疼痛、炎症、癌症、再狭窄、动脉粥样硬化、银屑病、血栓形成、与失髓鞘或脱髓鞘相关的疾病、障碍、损伤或功能障碍，或与神经生长因子（NGF）受体Trk-A、Trk-B和/或Trk-C异常活动相关的疾病或障碍的治疗。
• TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2858501A1

  公开（公告）日：2015-04-15
• US9181261B2
  申请人：——

  公开号：US9181261B2

  公开（公告）日：2015-11-10